The Research Pharmacy Core (RP) is essential to the translational work of MSKCC. The Core supports the ability of MSKCC to advance its scientific discoveries from laboratory-based investigations to clinical-based Proof-of-Concept testing. The RP has three principal components: 1) The Pharmaceutical Product Facility (PPF) for drug formulation/stability and compatibility issues; 2) The Clinical Grade Production (CGP) Facility for bulk product purification and vialing; and 3) the Pharmacy Investigational Drug Service (PIDS) which supports the preparation and packaging of Investigational drugs for preclinical and clinical use. The RP staff provide consultation, bulk product analysis and purification, formulation, vialing, labeling, stability/sterility testing, and dispensing. The RP works hand-in-hand with the Investigational Products Core to prepare the Chemistry, Manufacturing, and Control Section for each of MSKCC's IND's. Through the RP, MSKCC can advance internal ideas into early human testing. Owing to the infrastructure of the RP, MSKCC has been able to bring multiple distinct types of pharmacologic agents into early clinical trials. These include traditional small molecules, radiopharmaceuticals, and vaccines. The services provided by the core have supported the research of 24 investigators from 5 Programs and 49 IRB protocols in the last year. Since the last review, the work of the Core has contributed to 25 publications from 5 Programs. For example, the therapeutic antibody 3F8 is purified, manufactured, and vialed exclusively at MSKCC and forms the backbone of the research program in neuroblastoma. It has now been validated as an effective treatment for children with neuroblastoma. The large and complex vaccine program, integrating both carbohydrate and peptide vaccines on complex KLH backbone or in mixtures with novel adjuvants is also dependent on the services of the tripartite RP to support the clinical testing of vaccines against cancers Including serous ovarian cancer, leukemia, mesothelioma, and sarcoma.

Public Health Relevance

The Research Pharmacy provides services and expertise associated with the preparation, analysis and dispersion of investigational drugs. The Core is essential to the translational work at the Center and serves as a key conduit to deliver research discoveries from Center investigators to clinicians for human proof-of-concept testing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-52
Application #
9406253
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
52
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Basaraba, Cale N; Westhoff, Carolyn L; Pike, Malcolm C et al. (2017) Estimating systemic exposure to levonorgestrel from an oral contraceptive. Contraception 95:398-404
Hernandez, Jonathan M; Beylergil, Volkan; Goldman, Debra A et al. (2017) Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. Ann Surg :
Argani, Pedram; Kao, Yu-Chien; Zhang, Lei et al. (2017) Primary Renal Sarcomas With BCOR-CCNB3 Gene Fusion: A Report of 2 Cases Showing Histologic Overlap With Clear Cell Sarcoma of Kidney, Suggesting Further Link Between BCOR-related Sarcomas of the Kidney and Soft Tissues. Am J Surg Pathol 41:1702-1712
Moore, Kathleen N; Martin, Lainie P; O'Malley, David M et al. (2017) Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol 35:1112-1118
Lee, Ser Yee; Goh, Brian K P; Sadot, Eran et al. (2017) Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor. Ann Surg Oncol 24:202-210
Hyman, David M; Taylor, Barry S; Baselga, José (2017) Implementing Genome-Driven Oncology. Cell 168:584-599
Li, Gang G; Somwar, Romel; Joseph, James et al. (2017) Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. Clin Cancer Res 23:2981-2990
Bhagat, Tushar D; Zou, Yiyu; Huang, Shizheng et al. (2017) Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer. J Biol Chem 292:837-846
Prieto-Granada, Carlos N; Zhang, Lei; Antonescu, Cristina R et al. (2017) Primary cutaneous adenoid cystic carcinoma with MYB aberrations: report of three cases and comprehensive review of the literature. J Cutan Pathol 44:201-209
He, Mu; Agbu, Stephanie; Anderson, Kathryn V (2017) Microtubule Motors Drive Hedgehog Signaling in Primary Cilia. Trends Cell Biol 27:110-125

Showing the most recent 10 out of 7561 publications